Aardvark Therapeutics, Inc.
AARDNasdaq
$5.86
↓ -7.4%Jul 17 close · end-of-day
Price
1Y↓ -49.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$127.8M
Enterprise Value
$36.6M
P/E
—
P/S
—
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$69.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-80.3%
ROIC
—
Debt / Equity
—
Net Cash
$91.2M
Return 1Y
-51.0%
Company profile
We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We were incorporated in Delaware on May 17, 2017. Our principal executive offices are located at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA. We have one wholly-owned subsidiary, Artisan Therapeutics, Inc., incorporated in Delaware in October 2024.
- CEO
- Tien-Li Lee
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 18
- Headquarters
- California
- Website
- aardvarktherapeutics.com
Management & directors
- Lee Tien-LiChief Executive Officer
- Sun NelsonChief Financial Officer
- Jones BryanChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
AARD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.99↑ +39.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | $0.00 |
| Gross profit | — | — |
| Operating income | -$22.8M | -$62.7M |
| Net income | -$20.6M | -$57.6M |
| Diluted EPS | -$5.15 | -$2.93 |
| Operating cash flow | -$18.1M | -$54.2M |
| Free cash flow | -$18.2M | -$54.3M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.1M | -$5.1M | -$9.4M | -$10.5M | -$15.8M | -$17.7M | -$18.7M | -$22.5M |
| Net income | -$5.4M | -$4.2M | -$8.8M | -$9.3M | -$14.4M | -$16.3M | -$17.6M | -$21.6M |
| Diluted EPS | -$1.37 | -$1.05 | -$2.18 | -$0.71 | -$0.66 | -$0.75 | -$0.81 | -$0.99 |
| Operating cash flow | -$4.2M | -$4.0M | -$7.7M | -$11.4M | -$9.8M | -$16.1M | -$16.8M | -$18.9M |
| Free cash flow | -$4.3M | -$4.0M | -$7.7M | -$11.4M | -$9.9M | -$16.1M | -$16.8M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 28, 2026
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-11 | Lee Tien-Li· Chief Executive Officer | Buy | 7,000 | $14.49 | $101,395.00 | filing |
| 2025-12-11 | Sun Nelson· Chief Financial Officer | Buy | 3,000 | $14.40 | $43,200.00 | filing |
| 2025-10-15 | Jones Bryan· Chief Operating Officer | Option exercise | 1,250 | $4.24 | $5,300.00 | filing |
| 2025-10-15 | Lee Tien-Li· Chief Executive Officer | Option exercise | 1,229 | $4.24 | $5,210.96 | filing |
| 2025-09-15 | Lee Tien-Li· Chief Executive Officer | Buy | 6,500 | $9.51 | $61,818.90 | filing |
| 2025-09-15 | Lee Tien-Li· Chief Executive Officer | Buy | 3,500 | $9.94 | $34,804.70 | filing |
| 2025-09-12 | Lee Tien-Li· Chief Executive Officer | Buy | 5,000 | $8.50 | $42,515.50 | filing |
| 2025-09-11 | Lee Tien-Li· Chief Executive Officer | Buy | 6,000 | $7.82 | $46,926.00 | filing |
| 2025-09-10 | Lee Tien-Li· Chief Executive Officer | Buy | 9,000 | $7.91 | $71,212.50 | filing |
| 2025-08-28 | Lee Tien-Li· Chief Executive Officer | Option exercise | 17,209 | $4.24 | $72,966.16 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.